Eine Untersuchung zur Bedeutung und Umsetzung des monoklonalen Antikörpers Rituximab in der Versorgung von Patienten mit malignen Lymphomen im Einzugsgebiet des Tumorzentrums Regensburg (Regierungsbezirk Oberpfalz/Bayern)

Rüdiger Wolfgang Krause
2013
Prospective and randomized clinical trials have evidenced clearly improved surviving for patients with diffuse large B-cell lymphoma (DLBCL) in combination of standard chemotherapy plus Rituximab. Matter of this investigation was to replicate the benefit of surviving with routine data of a regional population-based sector- overlapping cancer registry. Progressing treatment data were evaluated from registry of Regensburg Tumor Center in Bavaria (for Patients living in the district "Oberpfalz")
more » ... rict "Oberpfalz") between 1998 and 2006 with a five years follow-up minimum. 866 Patients were distributed to following diagnoses: -high-grade-Non-Hodgkin lymphoma (hg-NHL) without Burkitt-Lymphoma, n=522 -follicular lymphoma (FL), n=176 -mantle-cell lymphoma (MCL), n=71 -indolent B-cell lymphoma, n=97 Patients with diagnosis hg-NHL have a significant better 5-year- outcome for overall survival with first-line with rituximab (77%) compared to conventional chemotherapy without rituximab (57,7%). Patients with indolent NHL also benefit from first-line therapy plus rituximab with 5-year overall survive outcome of 67% versus 53% without rituximab. Patients with diagnosis FL also have significant better overall survive outcome with early rituximab treatment (85,6%) compared to Patients without rituximab (53,1%). For Patients with mantle cell lymphoma (MCL) treated with or without rituximab there was not found any significant benefit for 5 year overall survive (with rituximab 33,4%, without38,9%, p=0,842). The progress and treatment analysis from the routine registry data of "Tumorzentrum Regensburg" in the district "Oberpfalz" in Bavaria essentially evidenced a survival benefit comparable to the results of clinical trials for defined classes of NHL. These findings generated with the approach of outcome research demonstrates the importance of nationwide collecting systems by progress- and population-based sector- overlapping cancer registries. In addition we realize the cancer registry data pool as a potential for verification of the quality [...]
doi:10.5283/epub.28037 fatcat:vfmbg4rsajhnzjnhsncfakgt6m